Business
ARIUS to present at 15th annual BioPartnering Europe conference
ARIUS to present at 15th annual BioPartnering Europe conference.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, Oct. 8 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced that David Young, MD, President and Chief Executive Officer of\nARIUS, has been invited to speak at the 15th annual BioPartnering Europe\nconference.\n\n\nDr. Young will present on Tuesday, October 9th at 11:45 am British Summer\nTime (BST) and will be available following his presentation. The conference is\nbeing held at the QEII Conference Centre in London, United Kingdom. Dr. Young\nwill provide an overview of the Company's business and unique technology and\nwill update the audience on milestones for the Company's lead programs in\ncancer. ARIUS has three lead programs focused on treatments for breast,\nprostate, colon and pancreatic cancers and is actively pursuing partnering\nopportunities to move the pipeline forward.\n\n\nThe BioPartnering Europe conference offers attendees an opportunity to\nmeet face-to-face with key players in the pharmaceutical and biotechnology\nindustry. Dr. Young will also be available for informal discussions during the\nOpen House Presentations on Monday, October 8th from 10:30 am-12:30 pm BST at\nBooth No. 20. Additional information about the 15th annual BioPartnering\nEurope conference can be found at: http://www.techvision.com/bpe/\n\n\nAbout ARIUS\n\n\nARIUS is a biotechnology company discovering and developing the next wave\nof antibody therapeutics. Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies and selects\nantibodies based on their functional ability to affect disease. This antibody\ngeneration engine has enabled ARIUS to assemble a portfolio of more than 400\nantibody candidates. In addition to the antibodies it is developing in-house,\nARIUS has ongoing partnerships with key biotechnology and drug development\ncompanies. ARIUS is listed on the TSX under the symbol "ARI". For further\ninformation, visit www.ariusresearch.com\n\n\nForward-Looking Statements\n\n\nCertain statements in this news release constitute "forward-looking\nstatements" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown risks, uncertainties and other\nfactors that may cause our actual results to be ma...